Latest News

Acadia fails in attempt to expand use of antipsychotic to treat patients with depression



Acadia Pharmaceuticals reported negative results Monday from a pair of late-stage clinical trials seeking to expand the use of its antipsychotic medicine Nuplazid to patients with major depressive disorder. 

The two identically designed Phase 3 clinical trials involved 300 patients who hadn’t responded well to currently approved depression treatments. In both studies, Nuplazid failed to demonstrate an anti-depressive benefit compared to a placebo when given to patients alongside their current medicines.

Read the rest…

Source link

Related posts

Characterisation of the photosystem-I reaction centre complex

Newsemia

Coconut oil increases bad cholesterol

Newsemia

汉瑞祥和Vets First Choice宣布,依计划产生的新公司命名为Covetrus

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World